![]() |
||||
|
||||
|
|
||||
Re: gyn oncology followupFrom: A.C. (A.C.Evans@m.cc.utah.edu)Mon Nov 3 16:04:14 1997
On Mon, 3 Nov 1997 16:17:58 -0600, rradnich@dca.net (Robert Radnich, M.D.) wrote:
>These findings were discussed with our consulting oncologist and it was
I would not have, either. She was adequately staged.
>
What about Chi, et al. Gynecologic Oncology 67, 56-60 (1997)? Although
this study addresses the role of surgical cytoreduction in Stage 4b
patients, this patient is in a similar category, having not received
any adjuvant therapy following her primary surgery.
> I stand by what I said in my previous post on this subject. I would perform laparotomy, debulking, and assess the extent of disease as well as r/o other primary sites for the cancer. I would tailor the therapy to the findings at laparotomy. A.C. Evans, M.D., Ph.D. Division of Gynecologic Oncology Univ. of Utah, Salt Lake City (801) 581-7640 A.C.Evans@m.cc.utah.edu acevans@hsc.utah.edu
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Dec 2 05:22:01 2009 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.